Lysosomal-Associated Protein Transmembrane 5 Functions as a Novel Negative Regulator of Pathological Cardiac Hypertrophy

Lu Gao, Sen Guo, Rui Long, Lili Xiao, Rui Yao, Xiaolin Zheng, Yanzhou Zhang, Xiaofang WangFrontiers in Cardiovascular Medicine 2021 · DOI

TL;DR

Researchers have identified Lysosomal-Associated Protein Transmembrane 5 (LAPTM5) as a novel negative regulator of pathological cardiac hypertrophy. They found that LAPTM5 levels decrease during heart hypertrophy and that manipulating LAPTM5 levels can significantly impact cardiac remodeling, suggesting LAPTM5 as a potential therapeutic target for heart failure.

What Problem Does This Paper Address?

Pathological cardiac hypertrophy, characterized by the enlargement of cardiomyocytes, is a major contributor to heart failure and cardiovascular disease-related deaths. While the initial hypertrophic response can be compensatory, sustained hypertrophy leads to severe cardiac dysfunction, arrhythmias, and ultimately, heart failure. Despite extensive research into the complex regulatory networks involved, the precise mechanisms driving pathological cardiac hypertrophy and the subsequent heart failure remain unclear, leaving a critical need for new therapeutic targets. This paper investigates the role of LAPTM5, a protein primarily known for its functions in immune cells, in the context of cardiac hypertrophy, aiming to uncover its potential as a therapeutic target.

Methods

The study employed a multi-pronged approach to investigate LAPTM5's role in cardiac hypertrophy:

  • In Vivo Models:
    • Aortic Banding (AB) Surgery: Mice underwent surgical constriction of the aorta to induce pressure overload, mimicking pathological cardiac hypertrophy.
  • LAPTM5 Knockout (KO) Mice: Mice genetically engineered to lack LAPTM5 were used to assess the consequences of its absence.
  • AAV9-Mediated Gene Delivery: Adeno-associated virus serotype 9 (AAV9), known for its efficient cardiac tropism, was used to overexpress LAPTM5 in mouse hearts.
  • Echocardiography: Non-invasive ultrasound imaging was used to assess cardiac structure and function (e.g., left ventricular dimensions, ejection fraction).
  • Histological Analysis: Heart tissues were stained (H&E for general morphology, Picrosirius Red for fibrosis) to evaluate cardiac remodeling, cardiomyocyte size, and fibrosis.
  • Western Blotting: Protein levels of cardiac hypertrophy markers (e.g., β-MHC, ANP) and signaling pathway components were quantified.
  • Real-Time PCR: mRNA levels of hypertrophy and fibrosis markers were measured.
  • In Vitro Models:
    • Neonatal Rat Cardiomyocyte (NRCM) Culture: Primary cardiomyocytes were isolated and cultured.
  • Adenovirus-Mediated Gene Delivery: Adenoviruses were used to overexpress LAPTM5 (AdLAPTM5) or knockdown LAPTM5 (AdshLAPTM5) in NRCMs.
  • Angiotensin II (Ang II) Stimulation: NRCMs were treated with Ang II, a known inducer of cardiac hypertrophy.
  • Immunofluorescence Staining: α-actinin staining was used to visualize cardiomyocyte morphology and measure cell surface area.
  • Western Blotting and Real-Time PCR: Similar to in vivo studies, these techniques were used to assess protein and mRNA levels in cultured cells.
  • Mechanistic Studies:
    • GST Pull-Down Assay: To investigate direct protein-protein interactions between LAPTM5 and Rac1.
  • Co-Immunoprecipitation (Co-IP) Assay: To confirm the interaction between LAPTM5 and Rac1.
  • Confocal Microscopy: To examine the subcellular colocalization of LAPTM5 and Rac1.
  • Constitutively Active Rac1 (G12V) Overexpression: To determine if Rac1 activity mediates LAPTM5's protective effects.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • LAPTM5 is a Cardiac Regulator: Contrary to its primary known roles in immune cells, this study reveals LAPTM5 is expressed in cardiomyocytes and plays a significant role in regulating cardiac hypertrophy. This expands our understanding of LAPTM5's tissue-specific functions.
  • LAPTM5 is Downregulated in Hypertrophy: The consistent observation of decreased LAPTM5 levels in both animal models and isolated cardiomyocytes under hypertrophic stress is a crucial finding, suggesting its downregulation contributes to the pathological process.
  • LAPTM5 Acts as a Protective Factor: Both in vivo (overexpression studies) and in vitro (overexpression studies), LAPTM5 demonstrates a protective effect against cardiac hypertrophy, reducing key markers and improving cardiac function. Conversely, its absence or knockdown exacerbates hypertrophy.
  • Rac1 is a Key Interactor: The study identifies Rac1 as a direct binding partner of LAPTM5. This interaction is central to LAPTM5's mechanism of action, suggesting that LAPTM5 exerts its protective effects by modulating Rac1 activity.
  • MEK-ERK Pathway Inhibition: The research demonstrates that LAPTM5's interaction with Rac1 leads to the inhibition of the MEK-ERK signaling pathway, a critical cascade involved in cardiac hypertrophy. This provides a concrete molecular mechanism for LAPTM5's cardioprotective role.
  • Therapeutic Potential: The findings strongly suggest that targeting LAPTM5, either by increasing its levels or activating its pathway, could be a promising therapeutic strategy for treating pathological cardiac hypertrophy and heart failure.

Key Results

  • LAPTM5 expression: Significantly decreased in hypertrophic mouse hearts and Ang II-treated cardiomyocytes.
  • LAPTM5 knockout mice: Showed exacerbated cardiac remodeling, increased hypertrophy, fibrosis, and impaired cardiac function after aortic banding compared to wild-type mice.
  • LAPTM5 overexpression (AAV9): Attenuated pressure overload-induced cardiac hypertrophy, reduced cardiac dilation, fibrosis, and improved ejection fraction in mice.
  • In vitro studies: Overexpression of LAPTM5 in NRCMs protected against Ang II-induced hypertrophy (reduced cell surface area, ANP, and β-MHC expression), while LAPTM5 knockdown exacerbated it.
  • Mechanistic findings: LAPTM5 directly interacts with Rac1. LAPTM5 overexpression inhibited MEK1/2 and ERK1/2 phosphorylation, while LAPTM5 knockdown increased it. The protective effect of LAPTM5 was blocked by a constitutively active Rac1 mutant (G12V).

Limitations and Future Work

  • Mechanism of LAPTM5 Downregulation: The study notes that the mechanism by which LAPTM5 is downregulated during cardiac hypertrophic progression in cardiomyocytes is unknown and requires further investigation.
  • Rac1 Lysosomal Degradation/Modification: While LAPTM5 binds to Rac1, the precise mechanism by which LAPTM5 influences Rac1 activity (e.g., lysosomal degradation or protein modification) remains unclear and warrants further exploration.
  • Broader Therapeutic Implications: While the study highlights therapeutic potential, further research is needed to fully elucidate the complex interactions and to develop targeted therapies.
  • Clinical Translation: The findings are primarily from preclinical models, and translation to human clinical applications would require extensive further studies.

Summary updated

Abstract

Lysosomal-associated protein transmembrane 5 (LAPTM5) is mainly expressed in immune cells and has been reported to regulate inflammation, apoptosis and autophagy. Although LAPTM5 is expressed in the heart, whether LAPTM5 plays a role in regulating cardiac function remains unknown. Here, we show that the expression of LAPTM5 is dramatically decreased in murine hypertrophic hearts and isolated hypertrophic cardiomyocytes. In this study, we investigated the role of LAPTM5 in pathological cardiac hypertrophy and its possible mechanism. Our results show that LAPTM5 gene deletion significantly exacerbates cardiac remodeling, which can be demonstrated by reduced myocardial hypertrophy, fibrosis, ventricular dilation and preserved ejection function, whereas the opposite phenotype was observed in LAPTM5 overexpression mice. In line with the <i>in vivo</i> results, knockdown of LAPTM5 exaggerated angiotensin II-induced cardiomyocyte hypertrophy in neonatal rat ventricular myocytes, whereas overexpression of LAPTM5 protected against angiotensin II-induced cardiomyocyte hypertrophy <i>in vitro</i>. Mechanistically, LAPTM5 directly bound to Rac1 and further inhibited MEK-ERK1/2 signaling, which ultimately regulated the development of cardiac hypertrophy. In addition, the antihypertrophic effect of LAPTM5 was largely blocked by constitutively active mutant Rac1 (G12V). In conclusion, our results suggest that LAPTM5 is involved in pathological cardiac hypertrophy and that targeting LAPTM5 has great therapeutic potential in the treatment of pathological cardiac hypertrophy.
BibTeX
@inproceedings{gao2021lysosomal,
  author = {Lu Gao and Sen Guo and Rui Long and Lili Xiao and Rui Yao and Xiaolin Zheng and Yanzhou Zhang and Xiaofang Wang},
  title = {{Lysosomal-Associated Protein Transmembrane 5 Functions as a Novel Negative Regulator of Pathological Cardiac Hypertrophy}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.740526},
}
Figure